HANXBIO-B(03378): HX111 completes the first case of patient medication.

HANXBIO-B (03378) has announced that the company has initiated a phase I clinical trial of its self-developed candidate drug HX111 (an OX40-targeted antibody-drug conjugate (ADC) candidate drug) for relapsed and refractory lymphoma and solid tumors. The first patient dosing has been successfully completed recently. HX111 can bind to the OX40 molecule on the surface of tumor cells with high affinity and specificity, and can efficiently enter tumor cells through endocytosis. It then releases a potent payload after being cleaved by lysosomal proteases, inducing tumor cell apoptosis. The OX40 molecule is highly expressed in some lymphomas and solid tumors, which currently lack effective treatment options, posing significant unmet clinical needs. HX111 developed by the company, is the first OX40-targeted ADC drug to enter clinical stages globally (First-in-Class, FIC). This field is still in its early exploration stage, and HX111 has a significant first-mover advantage and is expected to fill the gap in this field of tumor treatment in the future.